Caroline Siegel, MD, MS
Hospital for Special Surgery
New York, New York, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Megan Clowse, MD, MPH
Duke University
Chapel Hill, NC, United States
Disclosure(s): AstraZeneca: Consultant (Ongoing); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing)
Jennifer Grossman, MD
UCLA
Sherman Oaks, CA, United States
Disclosure(s): american board of internal medicine: Advisor or Review Panel Member (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); exact sciences: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); GlaxoSmithKlein(GSK): Grant/Research Support (Ongoing); ilumina: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); iqvia: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Lupus Foundation of America: Officer or Board Member (Ongoing); Merck/MSD: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); rheumatology research foundation: Grant/Research Support (Ongoing)
Patients with antiphospholipid syndrome, Sjogren's and systemic lupus erythematosus are at increased risk for obstetrical complications. This session will update the current state-of-the-art approach for management of these high-risk pregnancies.
Speaker: D. Ware Branch – University of Utah Health Sciences Center
Speaker: Peter Izmirly, MD – New York University Grossman School of Medicine
Speaker: Evelyne Vinet, MD, PhD, FRCPC – McGill University Health Centre